Share Price and Basic Stock Data
Last Updated: October 10, 2025, 1:47 am
| PEG Ratio | 31.27 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Hindustan Bio Sciences Ltd operates within the Trading & Distributors industry, with a current market capitalization of ₹8.46 Cr and a share price of ₹8.25. The company has shown fluctuating sales trends over recent quarters, with reported sales of ₹0.27 Cr in June 2022, which saw a slight increase to ₹0.33 Cr by March 2023. However, subsequent quarters recorded inconsistent performance, including a drop to ₹0.00 Cr in June 2023, before rebounding to ₹0.32 Cr in September 2023. The trailing twelve months (TTM) sales stand at ₹0.70 Cr, indicating challenges in maintaining consistent revenue generation. The company’s operational efficiency is further highlighted by a cash conversion cycle (CCC) of 198.27 days, suggesting delays in converting sales into cash, which could affect liquidity and operational agility. The overall sales trajectory remains concerning, particularly given the company’s reliance on public shareholders, who own 87.81% of the equity, reflecting a potential vulnerability to market sentiment.
Profitability and Efficiency Metrics
Hindustan Bio Sciences has reported profitability challenges, as evidenced by its operating profit margin (OPM) standing at 0.00% and a net profit of ₹0.10 Cr. The company recorded an operating loss in several quarters, with an operating profit of only ₹0.06 Cr in September 2023, suggesting significant inefficiencies in cost management. The return on equity (ROE) is reported at 11.8%, while the return on capital employed (ROCE) is notably low at 2.95%. The interest coverage ratio (ICR) is robust at 71.29x, indicating that the company comfortably meets its interest obligations, which is a positive sign amidst its profitability struggles. The overall profitability metrics suggest that while the company can manage its interest expenses well, operational efficiencies remain a critical area for improvement, especially considering the zero operating profit margins reported in several periods.
Balance Sheet Strength and Financial Ratios
The balance sheet of Hindustan Bio Sciences reveals a concerning picture with net reserves reported at -₹1.15 Cr and total borrowings of ₹2.51 Cr. The debt-to-equity ratio stands at 2.77x, indicating a high level of leverage, which may pose risks in times of financial stress. The current ratio is extraordinarily high at 73.31, suggesting excess liquidity, but this may also reflect inefficiencies in asset utilization. The company’s book value per share has seen a gradual decline, recorded at ₹0.88, which raises concerns about its long-term viability. The price-to-book value (P/BV) ratio is 7.91x, indicating that the market values the company significantly higher than its reported book value, hinting at investor optimism despite the underlying financial difficulties. The efficiency metrics, including ROCE at 2.95% and working capital days of 441.60, suggest challenges in managing operational capital effectively, which could impact future growth.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Hindustan Bio Sciences indicates a significant public ownership of 87.81%, while promoters hold a constant 12.19% stake. This distribution suggests a lack of institutional investor confidence, as there are no reported holdings from Foreign Institutional Investors (FIIs) or Domestic Institutional Investors (DIIs). The number of shareholders has gradually increased from 8,798 in September 2022 to 11,620 by June 2025, reflecting a growing interest from retail investors despite the company’s financial challenges. This increasing shareholder base could be interpreted as a positive sign for potential future liquidity and engagement. However, the absence of institutional backing might lead to volatility, especially in adverse market conditions. The stability of promoter holdings over time may indicate a commitment to the business, but the reliance on public shareholders could expose the company to market sentiment fluctuations.
Outlook, Risks, and Final Insight
If margins sustain improvements and operational efficiencies are realized, Hindustan Bio Sciences could enhance its profitability and attract institutional investors. The current operational challenges, including inconsistent revenue generation and high leverage, pose risks that need to be addressed urgently. The company’s ability to manage its cash conversion cycle effectively will be crucial in improving liquidity and operational agility. Additionally, maintaining a stable shareholder base while potentially diversifying ownership through institutional investments may bolster investor confidence. The financial metrics suggest that while there are strengths in interest coverage and a growing retail shareholder base, the risks associated with high debt levels and negative reserves warrant careful monitoring. If the company can leverage its current assets and manage costs more effectively, it may stabilize its financial performance and pave the way for future growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Hindustan Bio Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| MKP Mobility Ltd | 43.7 Cr. | 128 | 264/103 | 52.0 | 19.3 | 0.00 % | 19.6 % | 4.35 % | 10.0 |
| Mrugesh Trading Ltd | 0.34 Cr. | 1.39 | 1.39/0.48 | 0.99 | 73.5 | 0.00 % | 4.43 % | 3.81 % | 1.00 |
| Mukta Agriculture Ltd | 6.22 Cr. | 2.87 | 7.84/2.66 | 10.3 | 0.00 % | 0.57 % | 0.63 % | 10.0 | |
| Hindustan Bio Sciences Ltd | 8.46 Cr. | 8.25 | 13.5/6.70 | 282 | 0.88 | 0.00 % | 2.95 % | 11.8 % | 2.00 |
| Hindustan Appliances Ltd | 107 Cr. | 106 | 402/85.0 | 888 | 14.6 | 0.00 % | 0.30 % | 1.03 % | 10.0 |
| Industry Average | 257.50 Cr | 91.09 | 253.04 | 33.93 | 0.00% | 6.43% | 5.06% | 7.17 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.27 | 0.00 | 0.32 | 0.33 | 0.00 | 0.32 | 0.32 | 0.39 | 0.41 | 0.00 | 0.00 | 0.38 | 0.32 |
| Expenses | 0.29 | 0.07 | 0.27 | 0.31 | 0.12 | 0.26 | 0.26 | 0.35 | 0.34 | 0.05 | 0.04 | 0.28 | 0.32 |
| Operating Profit | -0.02 | -0.07 | 0.05 | 0.02 | -0.12 | 0.06 | 0.06 | 0.04 | 0.07 | -0.05 | -0.04 | 0.10 | 0.00 |
| OPM % | -7.41% | 15.62% | 6.06% | 18.75% | 18.75% | 10.26% | 17.07% | 26.32% | 0.00% | ||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.02 | -0.07 | 0.05 | 0.02 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.03 | -0.07 | 0.05 | 0.01 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
| EPS in Rs | -0.03 | -0.07 | 0.05 | 0.01 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
Last Updated: August 19, 2025, 1:50 pm
Below is a detailed analysis of the quarterly data for Hindustan Bio Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.32 Cr.. The value appears to be declining and may need further review. It has decreased from 0.38 Cr. (Mar 2025) to 0.32 Cr., marking a decrease of 0.06 Cr..
- For Expenses, as of Jun 2025, the value is 0.32 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.28 Cr. (Mar 2025) to 0.32 Cr., marking an increase of 0.04 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value appears to be declining and may need further review. It has decreased from 26.32% (Mar 2025) to 0.00%, marking a decrease of 26.32%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.11 (Mar 2025) to 0.01, marking a decrease of 0.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 12:57 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.25 | 0.75 | 1.26 | 1.01 | 1.03 | 3.56 | 1.94 | 1.03 | 0.43 | 0.92 | 1.05 | 0.81 | 0.70 |
| Expenses | 2.96 | 1.97 | 1.38 | 1.48 | 3.38 | 3.43 | 1.80 | 1.97 | 0.94 | 0.95 | 0.99 | 0.71 | 0.69 |
| Operating Profit | -0.71 | -1.22 | -0.12 | -0.47 | -2.35 | 0.13 | 0.14 | -0.94 | -0.51 | -0.03 | 0.06 | 0.10 | 0.01 |
| OPM % | -31.56% | -162.67% | -9.52% | -46.53% | -228.16% | 3.65% | 7.22% | -91.26% | -118.60% | -3.26% | 5.71% | 12.35% | 1.43% |
| Other Income | -0.04 | -0.01 | -1.92 | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Interest | 0.03 | 0.03 | 0.03 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.22 | 0.18 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Profit before tax | -1.00 | -1.44 | -2.08 | -0.49 | -2.27 | 0.11 | 0.12 | -0.96 | -0.51 | -0.04 | 0.05 | 0.10 | 0.03 |
| Tax % | 0.00% | 0.69% | 0.00% | 0.00% | 0.00% | 0.00% | 33.33% | -2.08% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -0.99 | -1.46 | -2.09 | -0.49 | -2.28 | 0.11 | 0.08 | -0.94 | -0.52 | -0.04 | 0.06 | 0.10 | 0.03 |
| EPS in Rs | -0.97 | -1.42 | -2.04 | -0.48 | -2.22 | 0.11 | 0.08 | -0.92 | -0.51 | -0.04 | 0.06 | 0.10 | 0.03 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -47.47% | -43.15% | 76.56% | -365.31% | 104.82% | -27.27% | -1275.00% | 44.68% | 92.31% | 250.00% | 66.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 4.32% | 119.71% | -441.86% | 470.13% | -132.10% | -1247.73% | 1319.68% | 47.63% | 157.69% | -183.33% |
Hindustan Bio Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: July 25, 2025, 1:06 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 2.05 | 2.05 | 2.05 |
| Reserves | -1.83 | -3.34 | -5.43 | -5.92 | -8.20 | -8.09 | -8.01 | -8.95 | -9.46 | -1.30 | -1.25 | -1.15 |
| Borrowings | 0.77 | 0.97 | 0.94 | 1.30 | 1.57 | 3.37 | 2.60 | 1.86 | 2.17 | 2.46 | 2.56 | 2.51 |
| Other Liabilities | 0.48 | 0.17 | 0.12 | 0.24 | 0.09 | 0.10 | 0.71 | 0.32 | 0.02 | 0.08 | 0.01 | 0.01 |
| Total Liabilities | 9.67 | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 |
| Fixed Assets | 0.16 | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
| CWIP | 1.92 | 1.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 7.59 | 6.05 | 5.81 | 5.81 | 3.65 | 5.57 | 5.50 | 3.44 | 2.94 | 3.26 | 3.34 | 3.39 |
| Total Assets | 9.67 | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 |
Below is a detailed analysis of the balance sheet data for Hindustan Bio Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 2.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.05 Cr..
- For Reserves, as of Mar 2025, the value is -1.15 Cr.. The value appears to be improving (becoming less negative). It has improved from -1.25 Cr. (Mar 2024) to -1.15 Cr., marking an improvement of 0.10 Cr..
- For Borrowings, as of Mar 2025, the value is 2.51 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 2.56 Cr. (Mar 2024) to 2.51 Cr., marking a decrease of 0.05 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.01 Cr..
- For Total Liabilities, as of Mar 2025, the value is 3.42 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.37 Cr. (Mar 2024) to 3.42 Cr., marking an increase of 0.05 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.03 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 3.34 Cr. (Mar 2024) to 3.39 Cr., marking an increase of 0.05 Cr..
- For Total Assets, as of Mar 2025, the value is 3.42 Cr.. The value appears strong and on an upward trend. It has increased from 3.37 Cr. (Mar 2024) to 3.42 Cr., marking an increase of 0.05 Cr..
However, the Borrowings (2.51 Cr.) are higher than the Reserves (-1.15 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.48 | -2.19 | -1.06 | -1.77 | -3.92 | -3.24 | -2.46 | -2.80 | -2.68 | -2.49 | -2.50 | -2.41 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 202.78 | 155.73 | 136.15 | 169.85 | 113.40 | 171.22 | 255.88 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 |
| Inventory Days | 36.08 | 25.08 | 0.00 | 0.00 | 51.23 | 13.89 | 95.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days Payable | 84.88 | 39.01 | 44.82 | 7.58 | 185.31 | |||||||
| Cash Conversion Cycle | 153.97 | 141.80 | 136.15 | 169.85 | 119.80 | 177.54 | 166.03 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 |
| Working Capital Days | 186.56 | 111.93 | -63.73 | -191.53 | -170.10 | 85.10 | 86.55 | -148.83 | -500.81 | -226.14 | 312.86 | 441.60 |
| ROCE % | -9.91% | -16.40% | -1.91% | -8.43% | -49.08% | 2.62% | 2.51% | -23.75% | -16.67% | -1.30% | 1.52% | 2.95% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.10 | 0.06 | -0.04 | -0.50 | -0.92 |
| Diluted EPS (Rs.) | 0.10 | 0.06 | -0.04 | -0.50 | -0.92 |
| Cash EPS (Rs.) | 0.09 | 0.06 | -0.03 | -0.50 | -0.90 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.88 | 0.78 | 0.72 | 0.76 | 1.27 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.88 | 0.78 | 0.72 | 0.76 | 1.27 |
| Revenue From Operations / Share (Rs.) | 0.79 | 1.03 | 0.89 | 0.42 | 1.01 |
| PBDIT / Share (Rs.) | 0.09 | 0.06 | -0.02 | -0.49 | -0.91 |
| PBIT / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.49 | -0.92 |
| PBT / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.50 | -0.93 |
| Net Profit / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.50 | -0.91 |
| PBDIT Margin (%) | 12.27 | 6.06 | -3.05 | -117.53 | -91.13 |
| PBIT Margin (%) | 12.24 | 5.41 | -3.67 | -118.32 | -91.91 |
| PBT Margin (%) | 12.07 | 5.06 | -4.11 | -119.47 | -92.57 |
| Net Profit Margin (%) | 12.39 | 5.47 | -4.38 | -120.18 | -91.07 |
| Return on Networth / Equity (%) | 11.13 | 7.16 | -5.41 | -65.75 | -72.04 |
| Return on Capital Employeed (%) | 2.92 | 1.69 | -1.81 | -27.41 | -46.54 |
| Return On Assets (%) | 2.94 | 1.70 | -1.23 | -17.39 | -26.95 |
| Long Term Debt / Equity (X) | 2.77 | 3.18 | 1.50 | 1.36 | 0.56 |
| Total Debt / Equity (X) | 2.77 | 3.18 | 3.29 | 2.75 | 1.42 |
| Asset Turnover Ratio (%) | 0.23 | 0.31 | 0.29 | 0.13 | 0.22 |
| Current Ratio (X) | 73.31 | 69.04 | 0.60 | 0.48 | 0.72 |
| Quick Ratio (X) | 73.31 | 69.04 | 0.60 | 0.48 | 0.72 |
| Interest Coverage Ratio (X) | 71.29 | 17.33 | -6.88 | -101.64 | -136.86 |
| Interest Coverage Ratio (Post Tax) (X) | 73.00 | 16.63 | -8.87 | -102.94 | -135.78 |
| Enterprise Value (Cr.) | 9.65 | 9.95 | 7.81 | 6.48 | 4.92 |
| EV / Net Operating Revenue (X) | 11.86 | 9.45 | 8.47 | 15.06 | 4.77 |
| EV / EBITDA (X) | 96.69 | 155.82 | -277.11 | -12.81 | -5.23 |
| MarketCap / Net Operating Revenue (X) | 8.80 | 7.06 | 5.91 | 10.05 | 2.98 |
| Price / BV (X) | 7.91 | 9.24 | 7.31 | 5.50 | 2.36 |
| Price / Net Operating Revenue (X) | 8.80 | 7.06 | 5.91 | 10.05 | 2.98 |
| EarningsYield | 0.01 | 0.01 | -0.01 | -0.11 | -0.30 |
After reviewing the key financial ratios for Hindustan Bio Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.10, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.10, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 3. It has increased from 0.06 (Mar 24) to 0.09, marking an increase of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.88. It has increased from 0.78 (Mar 24) to 0.88, marking an increase of 0.10.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.88. It has increased from 0.78 (Mar 24) to 0.88, marking an increase of 0.10.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.79. It has decreased from 1.03 (Mar 24) to 0.79, marking a decrease of 0.24.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 2. It has increased from 0.06 (Mar 24) to 0.09, marking an increase of 0.03.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 2. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 12.27. This value is within the healthy range. It has increased from 6.06 (Mar 24) to 12.27, marking an increase of 6.21.
- For PBIT Margin (%), as of Mar 25, the value is 12.24. This value is within the healthy range. It has increased from 5.41 (Mar 24) to 12.24, marking an increase of 6.83.
- For PBT Margin (%), as of Mar 25, the value is 12.07. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 12.07, marking an increase of 7.01.
- For Net Profit Margin (%), as of Mar 25, the value is 12.39. This value exceeds the healthy maximum of 10. It has increased from 5.47 (Mar 24) to 12.39, marking an increase of 6.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.13. This value is below the healthy minimum of 15. It has increased from 7.16 (Mar 24) to 11.13, marking an increase of 3.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.92. This value is below the healthy minimum of 10. It has increased from 1.69 (Mar 24) to 2.92, marking an increase of 1.23.
- For Return On Assets (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 5. It has increased from 1.70 (Mar 24) to 2.94, marking an increase of 1.24.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 2.77. This value exceeds the healthy maximum of 1. It has decreased from 3.18 (Mar 24) to 2.77, marking a decrease of 0.41.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.77. This value exceeds the healthy maximum of 1. It has decreased from 3.18 (Mar 24) to 2.77, marking a decrease of 0.41.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.23. It has decreased from 0.31 (Mar 24) to 0.23, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 73.31. This value exceeds the healthy maximum of 3. It has increased from 69.04 (Mar 24) to 73.31, marking an increase of 4.27.
- For Quick Ratio (X), as of Mar 25, the value is 73.31. This value exceeds the healthy maximum of 2. It has increased from 69.04 (Mar 24) to 73.31, marking an increase of 4.27.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 71.29. This value is within the healthy range. It has increased from 17.33 (Mar 24) to 71.29, marking an increase of 53.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 73.00. This value is within the healthy range. It has increased from 16.63 (Mar 24) to 73.00, marking an increase of 56.37.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9.65. It has decreased from 9.95 (Mar 24) to 9.65, marking a decrease of 0.30.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 11.86. This value exceeds the healthy maximum of 3. It has increased from 9.45 (Mar 24) to 11.86, marking an increase of 2.41.
- For EV / EBITDA (X), as of Mar 25, the value is 96.69. This value exceeds the healthy maximum of 15. It has decreased from 155.82 (Mar 24) to 96.69, marking a decrease of 59.13.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.80. This value exceeds the healthy maximum of 3. It has increased from 7.06 (Mar 24) to 8.80, marking an increase of 1.74.
- For Price / BV (X), as of Mar 25, the value is 7.91. This value exceeds the healthy maximum of 3. It has decreased from 9.24 (Mar 24) to 7.91, marking a decrease of 1.33.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.80. This value exceeds the healthy maximum of 3. It has increased from 7.06 (Mar 24) to 8.80, marking an increase of 1.74.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hindustan Bio Sciences Ltd:
- Net Profit Margin: 12.39%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.92% (Industry Average ROCE: 6.43%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.13% (Industry Average ROE: 5.06%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 73
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 73.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 282 (Industry average Stock P/E: 253.04)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.77
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.39%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | H.No.8-2-269/S, Plot No.31, Sagar Co-Operative Housing Society, Hyderabad Telangana 500034 | pharma.hindustanbio@gmail.com www.hindustanbiosciences.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. J V R Mohan Raju | Chairman & Managing Director |
| Mrs. J Uma | Director |
| Mr. Jaison George | Director |
| Mr. Reji Abraham | Independent Director |
| Mr. B Nagi Reddy | Independent Director |
| Mr. G Prateek Reddy | Independent Director |
FAQ
What is the intrinsic value of Hindustan Bio Sciences Ltd?
Hindustan Bio Sciences Ltd's intrinsic value (as of 10 October 2025) is 23.89 which is 189.58% higher the current market price of 8.25, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹8.46 Cr. market cap, FY2025-2026 high/low of 13.5/6.70, reserves of ₹-1.15 Cr, and liabilities of 3.42 Cr.
What is the Market Cap of Hindustan Bio Sciences Ltd?
The Market Cap of Hindustan Bio Sciences Ltd is 8.46 Cr..
What is the current Stock Price of Hindustan Bio Sciences Ltd as on 10 October 2025?
The current stock price of Hindustan Bio Sciences Ltd as on 10 October 2025 is 8.25.
What is the High / Low of Hindustan Bio Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hindustan Bio Sciences Ltd stocks is 13.5/6.70.
What is the Stock P/E of Hindustan Bio Sciences Ltd?
The Stock P/E of Hindustan Bio Sciences Ltd is 282.
What is the Book Value of Hindustan Bio Sciences Ltd?
The Book Value of Hindustan Bio Sciences Ltd is 0.88.
What is the Dividend Yield of Hindustan Bio Sciences Ltd?
The Dividend Yield of Hindustan Bio Sciences Ltd is 0.00 %.
What is the ROCE of Hindustan Bio Sciences Ltd?
The ROCE of Hindustan Bio Sciences Ltd is 2.95 %.
What is the ROE of Hindustan Bio Sciences Ltd?
The ROE of Hindustan Bio Sciences Ltd is 11.8 %.
What is the Face Value of Hindustan Bio Sciences Ltd?
The Face Value of Hindustan Bio Sciences Ltd is 2.00.